MRI of Transgene Expression: Correlation to Therapeutic Gene Expression  by Ichikawa, Tomotsugu et al.
MRI of Transgene Expression: Correlation to Therapeutic Gene
Expression
Tomotsugu Ichikawa*, Dagmar Ho¨gemanny, Yoshinaga Saeki*, Edyta Tyminski*, Kinya Terada*,
Ralph Weissledery, E. Antonio Chiocca* and James P. Basilion*,y,z
*Neurosurgical Service and Molecular Neuro-Oncology Laboratory,yCenter for Molecular Imaging Research,
zNFCR-Center for Molecular Analysis and Imaging, Department of Radiology, Massachusetts General Hospital,
Harvard Medical School, Boston, MA 02129, USA
Abstract
Magnetic resonance imaging (MRI) can provide high-
resolution 3D maps of structural and functional infor-
mation, yet its use of mapping in vivo gene expression
has only recently been explored. A potential application
for this technology is to noninvasively image transgene
expression. The current study explores the latter using a
nonregulatable internalizing engineered transferrin re-
ceptor (ETR) whose expression can be probed for with a
superparamagnetic Tf -CLIO probe. Using an HSV-
based amplicon vector system for transgene delivery,
we demonstrate that: 1) ETR is a sensitive MR marker
gene; 2) several transgenes can be efficiently expressed
from a single amplicon; 3) expression of each transgene
results in functional gene product; and 4) ETR gene
expression correlates with expression of therapeutic
genes when the latter are contained within the same
amplicon. These data, taken together, suggest that
MRI of ETR expression can serve as a surrogate for
measuring therapeutic transgene expression.
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Introduction
Severe side effects of many conventional anticancer agents
have driven the search for alternative anticancer drugs and
biologics to maximize the therapeutic efficacy while minimiz-
ing side effects. Among the strategies attempted, combina-
tion of biologics and chemotherapeutic agents in the form of
transgene therapy and prodrug administration has shown
some promise. Prodrug-activating gene therapy, as it has
come to be called, attempts to sensitize cells to prodrugs by
delivery of exogenous therapeutic genes. This approach has
shown positive results in several different laboratory models
[1–6] and these successes have spawned clinical trials [7–
10]. For gene therapy, regardless of the transgene used, it
would be a major advance to be able to monitor the efficiency
of transgene expression in target tissues noninvasively, in
real time, and at high spatial resolution. This would allow
precise determination of productive transduction of diseased
tissues, improve understanding of the temporal expression of
the transgene, and eventually result in maximum prodrug
activation in situ. Several different imaging modalities (e.g.,
nuclear and optical ) are being using to monitor real - time
transgene expression noninvasively and in vivo [11–14] and
in clinical applications [15]. However, none of these modal-
ities has the high spatial resolution of magnetic resonance
imaging (MRI) and would need to be combined with another
imaging modality (such as CT scan or MRI) to obtain ana-
tomical information [15]. Therefore, using a single modality
for both transgene monitoring and obtaining high-resolution
anatomical information would be highly desirable.
Others have used magnetic resonance spectroscopy
(MRS) to monitor transgene expression in vivo [16–18].
We have been developing MRI technology for monitoring
gene expression and have demonstrated the utility of MRI for
imaging gene expression both in vitro and in vivo as well as
its utility for mapping transgene expression in tumor sections
at microscopic resolution [19]. MRI at clinical field strengths
results in high soft tissue contrast anatomical images with
voxel resolutions in the 101 to 102 m3 range, but, contrasted
to the other imaging modalities, MRI suffers from lower
sensitivity to reporter probes. We have developed an
amplification scheme to overcome this limitation and have
pioneered the use of MR for in vivo imaging of transgene
expression employing the engineered transferrin receptor
(ETR) in cells transfected with transgenes ex vivo [19,20].
Recently, we have synthesized novel ETR-targeted MR
contrast agents [21] and further improved the sensitivity of
MRI for detection of ETR by 16- fold. Here we present a gene
therapy vector that contains several transgenes, one of which
is useful for prodrug therapy and the other for MRI of gene
expression. The work described demonstrates that HSV
amplicons can be used to simultaneously transfer several
genes into target cells, that the expression of each of the
transgenes is tightly correlated to the expression of the
contiguous genes, and that the therapeutic transgene can
enable effective prodrug-dependent cell killing, whereas the
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imaging transgene can allow for effective imaging of gene
expression in transduced cells.
Materials and Methods
Cell Lines
The Gli36@EGFR human glioma cells were generated
from parental Gli36 cells (a gift from Dr. D. Louis, MGH/
HMS) by retroviral transduction of a cDNA coding for a
mutant EGF receptor (a gift from Drs. H.J. Huang and
Webster K. Cavenee [22] ) and subcutaneous passage in
nude mice. The Gli36@EGFR cell line used in these studies
was isolated from ground up tumors and maintained in tissue
culture in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, and 0.5 g/ml puromycin at 378C in 5% CO2.
HSV-1 Amplicon Vectors
The vectors used in this study were genetically engi-
neered HSV-1 amplicons. Three vectors were used for this
study, EZ-ETR-P450 (see Figure 1) and two control vectors
derived from EZ-ETR-P450, ETR( ) /P450( + ), and
ETR( + ) /P450( ). The parent vector, EZ-ETR-P450,
contained three experimental cDNA, the LacZ and CYP2B1
cDNA and also the engineered transferrin receptor (ETR)
cDNA under the control of the CAG promoter [23], a gift from
Prof. Jun- ichi Miyazaki at Osaka University (Osaka, Japan).
The control vector for imaging, ETR( ) /P450( + ), con-
tained the b -galactosidase cDNA, LacZ, under control of the
HSV-1 IE4/5 promoter and the cDNA for a P450 enzyme,
CYP2B1, under control of the CMV promoter, but lacked
ETR cDNA. For the chemosensitivity assay, the control
vector, ETR( + ) /P450( ), contained the b -galactosidase
cDNA, LacZ, under control of the HSV-1 IE4/5 promoter and
the ETR cDNA under control of the CAG promoter, but no
CYP2B1 gene. Each vector also contained 1) the packaging
signal and the oriS sequences of HSV-1, and 2) the EBNA-
1 and oriP gene of Epstein-Barr virus. The above HSV-1
vectors were propagated and concentrated as described by
Saeki et al. [24,25]. Viral titers were determined by
measuring LacZ- transducing units on Gli36@EGFR cells
after X-gal staining. @EGFR-transfected Gli36 cells were
used for these studies as expression of this protein allows for
increased tumorigenicity. These cells have been very well
characterized and the inclusion of the EGFR does not alter
the experiments or conclusion of the paper [26]. Vectors
were stored at 808C prior to their use. Procedures
involving viruses were performed in accordance with guide-
lines issued by the Harvard Office of Biological Safety.
Analysis of Gene Expression by Western Blotting
Immunoblot analysis was performed with an ECL kit
(Amersham, Buckinghamshire, England, UK). Cells were
lysed by incubating them for 1 minute on ice in cell lysis
buffer (50 mM Tris–HCl, pH 8.0, 250 mM NaCl, 0.1% SDS,
1% NP-40, 0.5% Na deoxycholate, 0.02% sodium azide,
and protease inhibitor ), and the protein content of the
supernatant was quantified with a DC protein assay kit (Bio-
Rad, Hercules, CA), according to the manufacturer’s
instructions. An equal volume of 2 Laemmli sample buffer
was added to the supernatant, and this was boiled for 5
minutes. Equal amounts of protein from each extract (50 g/
lane) were separated on 8% SDS polyacrylamide gels and
transferred onto nitrocellulose membranes (Hybond-P).
After blocking with 5% dry milk in TBS-T (20 mM Tris–
HCl, pH7.6, 137 mMNaCl, 0.1% Tween 20), the membranes
were incubated with the primary antibody for 1 hour at room
temperature. Primary antibodies used were sheep antihu-
man transferrin receptor antibodies (a gift from Dr. Caroline
A. Enns [27] ), rabbit anti–b -galactosidase antibody (Chem-
icon, Temecula, CA), rabbit antirat CYP2B1/2B2 antibody
(Chemicon), and antimouse anti–b -actin monoclonal anti-
body (Sigma, St. Louis, MO) as an internal control. After
washing, the membrane was incubated for 1 hour at room
temperature with horseradish peroxidase–conjugated sec-
ondary antibodies. The secondary antibodies used were
swine antigoat IgG (Boehringer Mannheim, Indianapolis,
IN), antimouse and antirabbit IgG included with the ECL kit
(Amersham). Staining was carried out using the ECL kit
according to the manufacturer’s instructions. Semiquantita-
tive assessment of Western blot data was performed by
scanning the photographic films and then quantifying the
intensity of the bands on the film using NIH Image 1.6.
Reported data have been corrected for background intensity.
Because no preflashing of the film was performed, those
data can only be described as semiquantitative.
Immunohistochemical Staining
Fluorescence microscopy was used to confirm the
presence or absence of ETR, LacZ, and P450 transgenes
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Figure 1. Schematic of EZ -ETR -P450 amplicon. Three transgene cDNA are
contained within the amplicon: 1 ) the LacZ cDNA under control of an IE 4 /5
promoter; 2 ) the ETR cDNA under control of the CAG promoter; and 3 ) the
cDNA for rat cytochrome c P450 2B1 (CYP) under control of the CMV
promoter. Sequences for EBNA-1, to allow for episomal maintenance in
mammalian cells, and the pac signal, to allow for packaging into empty HSV
virion capsids, are also included ( see Materials and Methods ).
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overexpression in the infected cells. Cells were plated on
12-mm microscope cover glass (Fisher Scientific, Pitts-
burgh, PA), placed in 12-well dishes (Falcon; Becton
Dickinson, Lincoln Park, NJ), and allowed to grow for 24
hours prior to the start of the experiment. Cells were then
infected with amplicon and incubated for another 24 hours,
fixed with 2% formaldehyde, rinsed with PBS (0.01 M
phosphate buffer, 0.15 M sodium chloride, pH 7.4) and
10% horse serum (Sigma). The expression of LacZ,
CYP2B1, or ETR expression was revealed by sequential
addition and staining of target -specific primary antibodies
followed by fluorescence microscopy at three different
wavelengths as follows. First fixed samples were incubated
for 1 hour with sheep antirat CYP2B1/2B2 polyclonal
antibody (Chemicon) diluted (1:100) in incubation buffer
(PBS with 10% horse serum and 0.2% saponin; Sigma).
Following incubation, cells were rinsed with the same buffer
and incubated with Cy5.5- labeled donkey antisheep IgG
(Jackson Immuno Research, West Grove, PA) diluted (1:
200) in incubation buffer. After three washes in incubation
buffer, cells were incubated for 1 hour with a mouse
antihuman transferrin receptor monoclonal antibody (clone
B3/25; Boehringer Mannheim) and a rabbit anti–b -galacto-
sidase polyclonal antibody (Chemicon) diluted (1:200) in
incubation buffer (PBS with 10% horse serum and 0.2%
saponin; Sigma). Following incubation, cells were rinsed with
the same buffer and incubated with FITC- labeled goat
antimouse IgG (Southern Biotechnology Associates, Bir-
mingham, AL) and rhodamine- labeled antirabbit IgG (Chem-
icon) diluted (1:500 and 1:200, respectively ) in incubation
buffer. After three washes, cover slips were mounted on the
microscopy slides (Fisher Scientific ) using Fluoromount-G
(Southern Biotechnology Associates). Cells were examined
with a fluorescence microscope equipped with triple fluores-
cent filter sets and a SenSys CCD camera connected to a
Macintosh computer [20].
In Vitro Therapeutic Efficacy
To show that transduction of the CYP2B1 gene sensitizes
cells to cyclophosphamide (CPA), Gli36@EGFR human
glioma cells were seeded in a 24-well plate at a density of
5104 cells /well, cultured for 24 hours, and then virus
administered; EZ-ETR-P450 (MOI: 0, 5) or ETR( + ) /
P450( ) (MOI: 5) as a control. Twenty- four hours after
infection, medium-containing CPA at various concentrations
ranging from 1 to 10,000 M was added. Three days after
CPA administration, the percentage of surviving cells was
determined to evaluate cell chemosensitivity to CPA. Live
cells were quantified using a hemocytometer.
MRI
To determine if we could detect increased cellular uptake
of Tf - targeted iron oxide particles by cells infected with
ETR( + ) amplicon, human glioma cells were infected with
EZ-ETR-P450 amplicon or ETR( ) /P450( + ) amplicon,
exposed to media containing the Tf-S-S-CLIO conjugate for
1 hour at 378C, washed with HBSS, trypsinized, and
rewashed in DMEM supplemented with 10% FBS. Cells
were then collected by centrifugation and cell pellets
resuspended in culture medium and transferred to 250-l
tubes. To form uniform pellets, the cells were again
centrifuged at 700 rpm for 2 minutes (Sorvall 7 RT; Kendro
Laboratory Products, Newtown, CT). To prevent drying and
susceptibility artifacts, the supernatant was not removed.
The tubes were placed into a water bath at room temperature
for MRI. MRI was performed with a clinical 1.5-T super-
conducting magnet (Signa 5.0; GE Medical Systems,
Milwaukee, WI) using a 5- in. surface coil. The imaging
protocol consisted of a multiecho sequence (SE, TR 3000
milliseconds, variable TE 16–100milliseconds). The 1.9 mm
imaging slice was carefully placed to avoid partial vol-
ume effects. At a field of view of 8 cm2 and a 256256
imaging matrix, each voxel had a size of 0.186 mm3. Tf-S-
S-CLIO imaging agent used for these studies was synthe-
sized as described in Ho¨gemann et al. [21]. The stock of Tf -
S-S-CLIO contained approximately four Tf molecules per
CLIO and the relaxivities of the particles were measured
using a 0.47-T table top minispec (R1: 32 [mM s]1; R2:
146 [mM s] 1).
Results
The goal of these studies was to facilitate noninvasive, real -
time MRI of therapeutic gene transfer and expression. For
these studies, we constructed a gene therapy vector that
would allow for simultaneous expression of multiple cDNA,
coding for therapeutic and imaging transgenes that would
enable ‘‘surrogate’’ noninvasive real - time imaging of ther-
apeutic transgene expression. The high capacity of HSV
amplicons compared to most other viral vectors (allowing up
to 150 kb of foreign DNA to be delivered) provides a suitable
vector with desirable characteristics for the studies per-
formed here [28]. We thus sought to determine if an
imagable marker gene delivered by an HSV amplicon also
expressing a therapeutic transgene could serve as a
surrogate for monitoring therapeutic transgene expression
in glioma cells.
Figure 1 provides a schematic of this construct named
EZ-ETR-P450. Three transgene cDNA are expressed from
this vector: 1) the b -galactosidase (LacZ) cDNA, 2) the ETR
cDNA, and 3) the cDNA for rat cytochrome P450 2B1
(CYP2B1). Sequences for EBNA-1 and OriP from Epstein-
Bar virus (EBV), to allow for episomal maintenance in
mammalian cells, and the OriS and pac signals from HSV-1,
to allow for DNA replication and packaging of the plasmid in
the presence of HSV helper functions, are also included [28].
To show that this HSV/EBV hybrid amplicon can express
protein from all three cDNA simultaneously, human glioma
Gli36@EGFR cells were infected and expression of each of
the transgenes was monitored by Western blot analysis
(Figure 2A ). Because Gli36@EGFR cells express the
endogenous form of the human transferrin receptor, the blot
in Figure 2A also shows a band present in the control lanes
( i.e., time point 0 or MOI of 0). However, there is a clear
increase in the signal from this band after amplicon infection,
indicating increased expression from the ETR cDNA in the
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amplicon. To determine if variations in gene expression
would be reflected similarly by all three gene products,
different levels of gene expression were obtained by
changing either viral dose (MOI) or time after viral infection.
Analysis under these conditions showed that expression of
all three gene products was tightly correlated at different
levels of gene expression (Figure 2, A and C ). Inspection of
the semiquantitative analysis of Western blot data in Figure
2C reveals that expression of CYP2B1, ETR, and LacZ
increases similarly and correlates with both MOI and time
after infection. These results thus indicate that multiple
transgenes can be expressed from amplicons infecting
glioma cells and that their expression is tightly correlated at
different levels of expression.
Infected cells were also analyzed immunohistochemically
to determine if expression of all three transgenes occurred
in the same cell. Figure 2B shows microscopic analysis of a
representative human glioma cell from a culture infected
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Figure 2. (A ) Correlation of transgene expression in cells infected with EZ -ETR -P450 amplicon. Gli36@EGFR cells were infected with amplicon containing three
transgenes. At the indicated times or MOI, cells were harvested and lysates subjected to analysis by Western blot to confirm expression of transgenes. Blots were
treated and signal - analyzed using NIH image as described in Materials and Methods. These data are plotted in (C ). When protein expression was assessed at
varying times after infection, a single MOI of 1 was used ( representative data, n=3 ). (B ) Expression of three cDNA after infection with EZ -ETR -P450 amplicon in
each cell. Cells were fixed and analyzed using three different antibodies specific for each protein product. Complexes were then visualized using a second antibody
conjugated to one of three different fluorochromes, each emitting at different wavelengths. All three gene products were expressed in all cells observed. Presented is
a representative cell from an experiment ( n=3 ). (C ) Graphical analysis of Western blot from (A ). The ECL signal from (A ) was captured on to photographic film,
scanned into the computer, and the resulting electronic figure analyzed using NIH Image.
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with the amplicon, EZ-ETR-P450. All three transgenes
were expressed in the same cell simultaneously. Control
cells incubated without primary antibody confirmed speci-
ficity of signal. The distribution of transgene targets is in
agreement with previous reports describing the subcellular
distribution of the transferrin receptor [29,30] and of
CYP2B1 [31,32].
Although we had previously shown that cells stably
transfected with ETR could be visualized by MRI [19–21],
we have not determined if cells infected by an ETR-
expressing viral vector could also be imaged by MRI.
Human Gli36@EGFR glioma cells were infected with either
the EZ-ETR-P450 vector [ETR( + ) /P450( + ) ] or with a
control vector [ETR( ) /P450( + ) ], identical to EZ-ETR-
P450 but lacking ETR cDNA, and then treated in culture with
different concentrations of the imaging probe, Tf -S-S-CLIO
[21]. It is evident that, at Tf -S-S-CLIO concentrations of
0.5 g/ml, changes in MRI signal intensity are detectable
in the wells containing ETR( + ) /P450( + )– infected cells
(Figure 3A ). Doses of probe that are at least 10 times higher
are required to produce the same change in signal intensity
in the wells containing control ETR( ) /P450( + )– infected
cells. Presumably this is due to the uptake of Tf -S-S-CLIO
through the endogenous TfR. Additionally, we demonstrated
that increasing the MOI during treatment of the cells with
amplicon resulted in greater changes in MR signal inten-
sities. In experiments where cells were infected with
amplicons at an MOI of 20 vs an MOI of 4, a 1.8- fold
change in T2 was measured and was in good accordance
with the difference in ETR expression measured by Western
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Figure 3. (A ) Detection of increased cellular uptake of Tf iron oxide particles by cells infected with EZ -ETR -P450 amplicon. Twenty - four hours after infection, the
cells were incubated for 1 hour with increasing concentrations of Tf -S -S -CLIO contrast agent, washed, pelleted into tissue culture tubes, and imaged in a clinical
GE 1.5 -T MRI. T2 -weighted MRI of wells containing cell pellets treated with Tf -S -S -CLIO in culture shows that EZ -ETR -P450– infected cells show a significant
signal decrease at 0.5 g /ml iron compared to cells infected with the ETR-negative control vector, ETR(  ) / P450( + ). To conserve probe and other reagents,
selective informative data points were measured for the EZ -ETR-P450– infected cells. The black square in the lower left corner is a place holder ( n=2,
representative experiment shown ). (B ) Infection of Gli36@EGFR cells with EZ -ETR -P450 confers prodrug sensitivity. Gli36@EGFR cells were infected with EZ -
ETR -P450 or control amplicon [ETR( + ) /P450(  ) ] in tissue culture and cell survival 72 hours after CPA treatment was quantified by cell counting. EZ -ETR -
P450– infected cells have significantly increased drug sensitivity compared to uninfected and control infected cells ( n=3 ).
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blots (data not shown and Figure 2C ). These data thus
show that ETR delivery (and relative overexpression) into
cells by a gene transfer vector can be imaged using MRI.
To confirm that therapeutic gene expression measured in
Western blots yielded functional gene product, the ability of
the expressed gene product to metabolize CPA was func-
tionally determined. Figure 3B shows that there is a
significant dose-dependent increase in cell killing (chemo-
sensitivity ) in cells treated with CPA and infected with
amplicons containing the CYP2B1 cDNA compared to un-
infected cells or cells infected with control amplicons
[ (ETR( + ) /P450( ) ]. Additionally, the b -galactosidase en-
zyme was functional as the infected cells stained ‘‘blue’’ upon
addition of the chromophore, X-gal (data not shown). These
data suggest that the LacZ cDNA could be replaced by
another therapeutic gene, making it possible to deliver and
express multiple prodrug-activating enzymes from a single
amplicon, potentially increasing efficacy of the gene therapy.
Discussion
The genomic revolution is enabling a more comprehensive
understanding of the molecular basis of disease and, for the
first time, molecular therapeutic approaches to correct
‘‘defects’’ can be attempted. Further, other advances have
allowed investigators to express xenogenes in cells, impart-
ing additional functions to the cells. Implicit in the evolution of
these approaches is the development of efficient gene
delivery vehicles for in vivo delivery of ‘‘corrective /addi-
tional’’ genes and the need to identify ways of monitoring
gene delivery and expression noninvasively and in vivo.
Here we demonstrate that a high-capacity, high-effi-
ciency HSV-based gene therapy vector is amendable for
noninvasive imaging of therapeutic transgene expression.
We reasoned that if relative expression of the different
transgenes expressed from a single vector was tightly
correlated and varied with the level of viral transduction, we
would be able to use an imagable marker gene to provide
readout on the expression of the other genes (e.g.,
therapeutic transgenes) expressed from within the same
viral vector. Therefore, we designed and produced a herpes
amplicon vector that expressed three different transgenes
(CYP2B1, ETR, and LacZ) under control of separate and
individual promoters (see Figure 1). The results presented
here are the first to demonstrate that expression of multiple
gene products from a single gene therapy vector can be
monitored using MRI. These data demonstrate that it is
possible to: 1) use different constitutive promoters to drive
the expression of several different transgenes from a single
amplicon; 2) that the expression of each of the transgenes is
closely correlated to the others at different levels of
expression; 3) that individual cells express all the gene
products simultaneously; and 4) that the function of the
individual transgenes is maintained.
By combining the HSV amplicon system with the ETR/Tf -
S-S-CLIO imaging system, we have taken advantage of the
qualities of each to generate a gene therapy vector with the
capacity to efficiently deliver a large number of genes into
target tissues whose expression can be surrogately moni-
tored noninvasively by MRI. The use of the HSV amplicon
vectors for devising this system has several significant
advantages over other viral transduction systems allowing
for the largest versatility in applying this imaging system to
biological questions. First, the amplicons have an enormous
capacity to carry exogenous DNA (up to 150 kb of added
DNA), making the delivery of several different therapeutic or
imaging transgenes (and use of other imaging modalities)
possible [33]. Second, generation of amplicons containing
novel gene products is relatively straightforward [33], Third,
HSV-encapsulated amplicons have a wide tropism (cross-
species), efficiently transducing both primary cells and cell
lines in vitro, and transducing a variety of tissues in vivo
[24,34]. Finally, packaged amplicons can be generated free
of any contaminating replication-competent helper virus
[25]. In addition to the attributes of the amplicon, imaging by
MRI has several useful features, including little to no toxicity
in vitro or in vivo for the parent iron oxide particles, relatively
rapid in vivo clearance of the imaging agent, iron oxide
nanoparticles [35], and high anatomical resolution of MRI.
These features potentially would permit excellent detection
of gene expression by MRI and are very convenient in
applications in which repeated evaluation of gene expression
over short periods of time is needed, potentially allowing for
repeated MRI in vivo as well as in vitro.
When using ETR as a surrogate marker for expression of
other transgenes, a potential limitation might be that
selective pressures in vitro differentially modulate expression
of the ETR reporter gene and the other transgenes. To
assess such interactions, we performed semiquantitative
Western Blots and qualitative immunohistochemical analysis
to demonstrate that expression of all three transgene
products appears to be linearly related to viral transduction
and that all three are expressed in all observed cells,
simultaneously. Therefore, the strategy to use different
promoters to drive each transgene within the same vector
is apparently not susceptible to the in vitro variations tested
here ( i.e., time after infection or MOI). These data also
suggest that the use of IRES-containing bicistronic mRNA
[36] is not necessary to achieve simultaneous and linear
expression ratios between gene products, in agreement with
other studies using separate adenoviral vectors [37].
Furthermore, the ability to employ strong promoters to drive
expression of both the therapeutic transgene and the
imaging transgene is advantageous compared to bicistronic
mRNA, which often show several - fold reduction in expres-
sion from genes placed downstream of the IRES. This vector
system may therefore prove to be advantageous when high
expression levels of both therapeutic and imaging trans-
genes are required or when the expression of two or more
transgenes is required.
We previously demonstrated that the imaging transgene,
ETR, was effective both in vivo and in vitro for MRI of
transgene expression when combined with targeted iron
oxide nanoparticles. Here we demonstrate that using a viral
transduction system, the ETR transgene can be success-
fully transferred into tissue culture cells, resulting in a
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significant change in T2-weighted MR signal intensity
(Figure 3A ). The change in signal was dependent on the
time after infection as well as MOI (data not shown),
suggesting that imaging the ETR transgene faithfully
represents transduction and expression efficiency as moni-
tored by Western blotting (Figure 2). These characteristics
would make the ETR transgene useful for following gene
transfer in vivo during gene therapy protocols. We also
demonstrated that infection of cells with the EZ-ETR-P450
amplicon resulted in increased sensitivity to prodrug admin-
istration (Figure 3B ). Taken together, these data demon-
strate the utility of this amplicon for imaging therapeutic
gene transfer and function.
Finally, because of the ability of this modality to generate
high-resolution anatomical images, this system may supple-
ment or replace systems, which use reporter genes in
transgenic animals to analyze tissue-specific promoters
sequences and/or effects of drugs or environment on gene
expression. Currently, nuclear and optical modalities are
limited to detecting changes in transgene expression without
being able to ascribe the tissue, or individual cells respon-
sible for signal generation. Using these (or other) MRI
transgenes may make it possible to assign gene expression
to small groups of cells within living animals and clearly
define tissues or cells permissive for transgene expression.
We are now performing studies aimed at moving these
therapeutic imaging vectors into in vivo studies including
pharmacokinetic analysis of contrast agents and HSV
amplicons.
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